SORLA Protein Identified as Potential Target to Combat Alzheimer's Tangles
1 min readCovered by 3 outlets

AI Summary
New research shows that boosting the SORLA protein can stop toxic tau tangles and brain shrinkage, offering a potential new path for Alzheimer's treatment.
Scientists at Sanford Burnham Prebys have found that increasing levels of the protein SORLA reduces toxic tau tangles and protects nerve cell connections in Alzheimer's models.
In a study published in Science Advances, researchers discovered that boosting the protein known as SORLA can mitigate several damaging changes linked to Alzheimer's disease. Experiments using mice demonstrated that higher levels of this protein helped prevent brain shrinkage and reduced the accumulation of abnormal tau proteins, according to reports from Health & Medicine News and ScienceDaily.
Tau proteins typically function to stabilize microtubules, which provide internal support for neurons. However, in conditions referred to as tauopathies, these proteins become abnormal and stick together to form tangles that disrupt nerve cell communication. The researchers found that strengthening SORLA levels not only reduced these tangles but also helped preserve the intricate networks that allow neurons to interact.
Timothy Huang, PhD, an assistant professor at Sanford Burnham Prebys, stated that while it was known SORLA could suppress amyloid-beta accumulation, its effect on tau tangles had been largely unknown. He noted that the research specifically addressed this missing piece of Alzheimer's pathology. The findings suggest that reinforcing the brain's internal defense mechanisms could potentially lead to new treatments for neurodegenerative diseases.
Background
The SORLA protein, or sorting-related receptor with A-type repeats, has been researched for nearly 20 years for its ability to limit amyloid-beta, which forms plaques in the brains of those with Alzheimer's.
How outlets covered it
The original reporting this article is drawn from. Each link opens the outlet's own article.
Get our daily briefing first.
We're starting a short daily email with the stories most outlets are covering. Join the list to get the first one.
Free. No spam.
Discussion
No comments yet. Be the first to start the conversation!